Immuneering Appoints Experienced CFO Andrew Gengos with Substantial Equity Inducement
IMRX has more than doubled off its 52-week low of $1.66.
Summary
Immuneering Corp appointed Andrew Gengos, a seasoned biopharmaceutical executive, as its new CFO, offering a substantial equity package to lead financial strategy during a critical growth phase.
Key Events · Executive and Board Changes · IMRX
-
New Chief Financial Officer Appointed
Andrew Gengos, an executive with extensive experience at Terns Pharmaceuticals, LeonaBio, Cyteir Therapeutics, and Amgen, was appointed Chief Financial Officer and Treasurer, effective by July 16, 2026.
-
Significant Equity Inducement Grant
Mr. Gengos will receive an option to purchase 650,000 shares of common stock as a material inducement to his employment.
-
Smooth Leadership Transition
Mr. Gengos will succeed Mallory Morales as principal financial officer, while Ms. Morales will continue in her role as Senior Vice President Finance, Chief Accounting Officer, and principal accounting officer.
Analysis · IMRX · Life Sciences
Immuneering Corp has appointed Andrew Gengos, an experienced biopharmaceutical finance executive, as its new Chief Financial Officer. This is a key hire for a clinical-stage biotech, especially as the company advances its lead drug atebimetinib into Phase 3 trials and manages its cash runway. The significant equity inducement package, including an option to purchase 650,000 shares, underscores the importance of this role and the company's commitment to attracting top talent.
At the time of this filing, IMRX was trading at $4.19 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $271.1M. The 52-week trading range was $1.66 to $10.08. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.